Study of ALXN1210 in Complement Inhibitor Treatment-Naïve Adult and Adolescent Participants With Atypical Hemolytic Uremic Syndrome (aHUS)

Atypical Hemolytic Uremic Syndrome (aHUS) Clinical Trial

Official title:

Single Arm Study of ALXN1210 in Complement Inhibitor Treatment-naïve Adult and Adolescent Patients With Atypical Hemolytic Uremic Syndrome (aHUS)

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02949128
• Other study ID #: ALXN1210-aHUS-311
• Secondary ID: 2016-002027-29
• Status: Completed
• Phase: Phase 3
• Start date: January 11, 2017
• Est. completion date: January 24, 2023

Study information

• Verified date: January 2024
• Source: Alexion Pharmaceuticals, Inc.
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of the study is to assess the safety and efficacy of ravulizumab to control disease activity in adolescent and adult participants with aHUS who had not previously used a complement inhibitor.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 58
• Est. completion date: January 24, 2023
• Est. primary completion date: January 24, 2023
• Accepts healthy volunteers: No
• Gender: All
• Age group: N/A and older

Eligibility

Inclusion Criteria:

1. Male or female = 12 years of age and weighing = 40 kg at the time of consent.

2. Evidence of thrombotic microangiopathy, including low platelet count, hemolysis (breaking of red blood cells inside of blood vessels), and decreased kidney function.

3. Documented meningococcal vaccination not more than 3 years prior to, or at the time of, initiating study drug. Participants who received a meningococcal vaccine less than 2 weeks before initiating ravulizumab treatment must have received treatment with appropriate prophylactic antibiotics until 2 weeks after vaccination. Participants who had not been vaccinated prior to initiating ravulizumab treatment should have received prophylactic antibiotics prior to and for at least 2 weeks after meningococcal vaccination. Participants < 18 years of age must have been vaccinated against haemophilus influenzae type b and streptococcus pneumoniae according to national and local vaccination schedule guidelines.

4. Female participants of childbearing potential and male participants with female partners of childbearing potential had to use highly effective contraception starting at screening and continuing until at least 8 months after the last dose of ravulizumab.

Exclusion Criteria:

1. A disintegrin and metalloproteinase with a thrombospondin type 1 motif, member 13 deficiency (activity < 5%).

2. Shiga toxin-related hemolytic uremic syndrome.

3. Positive direct Coombs test.

4. Pregnancy or breastfeeding.

5. Identified drug exposure-related hemolytic uremic syndrome (HUS).

6. Bone marrow transplant/hematopoietic stem cell transplant within last 6 months prior to start of Screening.

7. HUS related to known genetic defects of cobalamin C metabolism.

8. Systemic sclerosis (scleroderma), systemic lupus erythematosus, or antiphospholipid antibody positivity or syndrome.

9. Chronic dialysis (defined as dialysis on a regular basis as renal replacement therapy for end-stage kidney disease).

Related Conditions & MeSH terms

• Atypical Hemolytic Uremic Syndrome
• Atypical Hemolytic Uremic Syndrome (aHUS)
• Azotemia
• Hemolysis
• Hemolytic-Uremic Syndrome
• Syndrome

Intervention

Biological:
• Ravulizumab
Single loading dose on Day 1, followed by regular maintenance dosing beginning on Day 15, based on weight: = 40 to < 60 kilograms (kg), 2400 milligrams (mg) loading, then 3000 mg every 8 weeks; = 60 to < 100 kg, 2700 mg loading, then 3300 mg every 8 weeks; = 100 kg, 3000 mg loading, then 3600 mg every 8 weeks.

Locations

Country	Name	City	State
Australia	Clinical Trial Site	Clayton
Australia	Clinical Trial Site	Geelong
Australia	Clinical Trial Site	Parkville
Austria	Clinical Trial Site	Vienna
Belgium	Clinical Trial Site	Brussels
Canada	Clinical Trial Site	London
France	Clinical Trial Site	Bordeaux
France	Clinical Trial Site	Clermont-Ferrand
France	Clinical Trial Site	Lille
France	Clinical Trial Site	Montpellier
France	Clinical Trial Site	Nice
France	Clinical Trial Site	Paris
Germany	Clinical Trial Site	Aachen
Germany	Clinical Trial Site	Essen
Germany	Clinical Trial Site	Hanover
Germany	Clinical Trial Site	Muenchen
Germany	Clinical Trial Site	Tuebingen
Italy	Clinical Trial Site	Bologna
Italy	Clinical Trial Site	Firenze
Japan	Clinical Trial Site	Saitama
Japan	Clinical Trial Site	Tokyo
Korea, Republic of	Clinical Trial Site	Gyeonggi-do
Korea, Republic of	Clinical Trial Site	Seoul
Russian Federation	Clinical Trial Site	Moscow
Russian Federation	Clinical Trial Site	Saint Petersburg
Spain	Clinical Trial Site	Barcelona
Spain	Clinical Trial Site	Madrid
Spain	Clinical Trial Site	Valencia
Taiwan	Clinical Trial Site	Taichung
Taiwan	Clinical Trial Site	Taipei
Taiwan	Clinical Trial Site	Taipei City
United Kingdom	Clinical Trial Site	Cardiff
United Kingdom	Clinical Trial Site	London
United States	Clinical Trial Site	Columbus	Ohio
United States	Clinical Trial Site	Durham	North Carolina
United States	Clinical Trial Site	Fort Wayne	Indiana
United States	Clinical Trial Site	Fort Wayne	Indiana
United States	Clinical Trial Site	Winston-Salem	North Carolina

Sponsors (1)

Lead Sponsor	Collaborator
Alexion Pharmaceuticals, Inc.

Countries where clinical trial is conducted

United States,  Australia,  Austria,  Belgium,  Canada,  France,  Germany,  Italy,  Japan,  Korea, Republic of,  Russian Federation,  Spain,  Taiwan,  United Kingdom, 

References & Publications (1)

Barbour T, Scully M, Ariceta G, Cataland S, Garlo K, Heyne N, Luque Y, Menne J, Miyakawa Y, Yoon SS, Kavanagh D; 311 Study Group Members. Long-Term Efficacy and Safety of the Long-Acting Complement C5 Inhibitor Ravulizumab for the Treatment of Atypical He — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Percentage Of Participants With Complete Thrombotic Microangiopathy (TMA) Response at Week 26	Complete TMA response during the 26-week Initial Evaluation Period is a composite outcome measure that required normalization of hematological parameters (platelet count and lactate dehydrogenase [LDH]) and improvement in kidney function (=25% reduction in serum creatinine from baseline); for participants on dialysis, baseline was established at least 6 days after the end of dialysis. Participants had to meet these criteria for 2 separate assessments obtained at least 4 weeks (28 days) apart, and any measurement in between. To be considered a responder during the 26-week Initial Evaluation Period, the latest time point a participant could first meet the response criteria was 28 days before the Week 26 (Day 183) assessment. Formal statistical comparison analyses were not planned for this study. The percentage was based on the responders among treated participants. The 95% confidence interval (CI) was based on the asymptotic Gaussian approximation method with a continuity correction.	Week 26
Secondary	Time To Complete TMA Response	Participants that did not have a response were censored at the date of last visit or study discontinuation at the time when the analysis was performed. The time to complete TMA Response is reported in days. The time of the event of a confirmed complete TMA response was considered the first time point at which all the criteria for complete TMA response were met.	Baseline through Week 114
Secondary	Participants Who Do Not Require Dialysis at Weeks 26 and 52	For participants requiring dialysis within 5 days prior to ALXN1210 treatment initiation, the number of participants no longer requiring dialysis is reported	Week 26 and Week 52
Secondary	Proportion Of Participants With Complete TMA Response At Week 52	The proportion of participants considered responders, along with a 2-sided 95% CI for the Week 52 time point, is reported. To be considered a responder during the 26-week Initial Evaluation Period, the latest time point a participant could first meet the response criteria was 28 days before the Week 26 (Day 183) assessment (components of the response maintained for at least 28 days).	Week 52
Secondary	Change From Baseline In Estimated Glomerular Filtration Rate (eGFR) At Weeks 26 and 52	Kidney function evaluated by eGFR was summarized at baseline and the Week 26 and Week 52 time points using descriptive statistics for continuous variables for the observed value, as well as the change from baseline. The baseline value was defined as the average of the values from the assessments performed prior to the first study drug infusion (these could include results from Screening and the Day 1 visit). A value of 10 milliliters (mL)/minute (min)/1.73 meters squared (m^2) for eGFR was imputed for participants requiring dialysis for acute kidney injury. The observed value and change from baseline are reported in mL/min/1.73 m^2. An increase indicated improvement in kidney function.	Baseline, Week 26 and Week 52
Secondary	Participants With Change From Baseline In CKD Stage At Weeks 26 and 52	The CKD stage is presented as the change from baseline in the participants that Improved (excluding those with Stage 1 [normal renal function] at baseline as they cannot improve), Worsened (excluding those with Stage 5 at baseline as they cannot worsen), and Stayed the Same, compared to the CKD stage at baseline. Baseline was derived based on the last available eGFR before starting treatment. Stage 5 was considered the worst category, while Stage 1 was considered the best category. A 2-sided 95% CI for the proportion, based on exact confidence limits using the Clopper-Pearson method, was provided for each category. The CKD stage was classified based on the National Kidney Foundation Chronic Kidney Disease Stage.	Baseline, Week 26, and Week 52
Secondary	Change From Baseline In Platelet Count At Weeks 26 and 52	The hematologic TMA parameter of platelet count was summarized at baseline and at Week 26 and Week 52 using descriptive statistics for continuous variables for the change from baseline. Results are reported in platelets*10^9/liter (L) blood.	Baseline, Week 26 and Week 52
Secondary	Change From Baseline In LDH At Weeks 26 and 52	The hematologic TMA parameter of serum LDH was summarized at baseline and at Week 26 and Week 52 using descriptive statistics for continuous variables for the change from baseline. Results are reported in units (U)/L.	Baseline, Week 26 and Week 52
Secondary	Change From Baseline In Hemoglobin At Weeks 26 and 52	The hematologic TMA parameter of hemoglobin level was summarized at baseline and at Week 26 and Week 52 using descriptive statistics for continuous variables for the change from baseline. Results are reported in grams (g)/L.	Baseline, Week 26 and Week 52
Secondary	Percentage Of Complement Inhibitor Treatment-naïve Participants With An Increase From Baseline In Hemoglobin =20 g/L Through Week 26 and Week 52	The percentage of participants with an increase from baseline in hemoglobin =20 g/L, observed at 2 separate assessments obtained at least 4 weeks (28 days) apart, and any measurement in between, was assessed through Week 26 and Week 52 and is presented as the percentage of responders, along with a 2-sided 95% CI. The 95% CIs are based on exact confidence limits using the Clopper-Pearson method. To be considered a responder during the 26-week and 52-week Extension Periods, the latest time point a participant could first meet the response criteria was 28 days before the respective Week 26 and Week 52 assessments (components of the response maintained for at least 28 days).	Baseline through Week 26 and through Week 52
Secondary	Change From Baseline In Quality Of Life As Measured By The EuroQol 5-Dimension 3-Level (EQ-5D-3L) At Weeks 26 and 52	The EQ-5D-3L is a participant-answered questionnaire that scores 5 dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression (scored as a 1, 2, or 3, with 3 being the worst health state), as well as health state on a visual analogue scale (0 to 100, with 100 representing the best health state). From these scores, a summary index score is derived using the time trade-off valuation set for the United States and ranges from -1 to 1, where a score above 0.94 indicates full health. An increase in score from baseline indicates improvement in quality of life.	Baseline, Week 26 and Week 52
Secondary	Change From Baseline In Quality Of Life As Measured By The Functional Assessment Of Chronic Illness Therapy (FACIT)-Fatigue Version 4 Questionnaire At Weeks 26 and 52	Quality of life was evaluated in part using FACIT Fatigue Version 4. The data were summarized at baseline and at the Week 26 and Week 52 time point using descriptive statistics for continuous variables. The FACIT Fatigue Version 4 questionnaire at baseline and the Week 52 timepoint was scored using standard scoring algorithms. The score ranges from 0-52, with a higher score indicating less Fatigue. An increase in score indicated an improvement in quality of life.	Baseline, Week 26 and Week 52